zen3694,talazoparib
pfizer,zenith capital corporation
['bcsm', 'talazoparib', 'tnbc', 'brca', 'zen-3694 ']
pass by board 401 at this morning s poster session. we are presenting data from the phase 1/2 study of zen-3694 (bet inhibitor) in combination with talazoparib in brcawt metastatic tnbc.
a poster discussion will follow in hall b1 at 11h30 ct #asco22 #bcsm 
Med Onc, Clinical Trials Development Leader @JulesBordet #BreastCancer #PrecisionMedicine. Views are mine https://t.co/PeEXATwb02